Results 141 to 150 of about 4,766 (189)
Some of the next articles are maybe not open access.
Elvitegravir for the treatment of HIV
Expert Opinion on Pharmacotherapy, 2016Current antiretrovirals (ARVs) have demonstrated the ability to prolong the life of an HIV infected individual via suppression of the virus and subsequent restoration of immune function. Despite significant advancement, there remains an opportunity for improvement.
Nathan R Unger, Elizabeth M Sherman
exaly +4 more sources
Elvitegravir: a once-daily inhibitor of HIV-1 integrase
Expert Opinion on Investigational Drugs, 2012Elvitegravir (EVG) is a potent inhibitor of HIV-1 integrase (IN) undergoing Phase III clinical trials. It blocks the strand-transfer step in a multi-step process that allows double-stranded cDNA to be irreversibly incorporated within the host DNA. It is the second member of the HIV-1 IN inhibitor class, following raltegravir.
Todd, Wills, Vivian, Vega
exaly +3 more sources
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016 Dolutegravir and Elvitegravir belongs to a class of integrase inhibitors which has recently been approved by the FDA for the treatment of HIV-infection.
Sujan Dilly Penchala +2 more
exaly +3 more sources
Antiviral Therapy, 2008
Background This crossover, open-label clinical study evaluated the potential for clinically relevant drug interactions between ritonavir-boosted elvitegravir (elvitegravir/r), an HIV integrase inhibitor, and etravirine, a non-nucleoside reverse transcriptase inhibitor.
Srinivasan, Ramanathan +4 more
openaire +2 more sources
Background This crossover, open-label clinical study evaluated the potential for clinically relevant drug interactions between ritonavir-boosted elvitegravir (elvitegravir/r), an HIV integrase inhibitor, and etravirine, a non-nucleoside reverse transcriptase inhibitor.
Srinivasan, Ramanathan +4 more
openaire +2 more sources
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study [PDF]
HIV Medicine, 2019 Objectives: The aim of the study was to compare the efficacy and tolerability of switching antiretroviral therapy to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (TDF) with those of switching to elvitegravir/cobicistat/emtricitabine/TDF in ...
Gianmaria Baldin +2 more
exaly +2 more sources
An Improved Synthesis of Elvitegravir
Journal of Heterocyclic Chemistry, 2015An improved process for the active pharmaceutical ingredient of a new HIV integrase inhibitor elvitegravir (1) has been developed. It starts from commercially available 2,4‐dimethoxyacetophenone, which is selectively halogenated into the position 5. The 5‐halo acetophenones are condensed with dialkyl carbonates to give the corresponding benzoylacetates.
Stanislav Rádl +6 more
openaire +1 more source
Antiviral Research, 2012
Elvitegravir is a strand transfer inhibitor of HIV-1 integrase that is currently undergoing phase 3 clinical testing. The two predominant metabolites of elvitegravir, M1 and M4 (elvitegravir hydroxide and elvitegravir glucuronide), have been shown to inhibit HIV-1 integrase in vitro.
Nicolas A, Margot +7 more
openaire +2 more sources
Elvitegravir is a strand transfer inhibitor of HIV-1 integrase that is currently undergoing phase 3 clinical testing. The two predominant metabolites of elvitegravir, M1 and M4 (elvitegravir hydroxide and elvitegravir glucuronide), have been shown to inhibit HIV-1 integrase in vitro.
Nicolas A, Margot +7 more
openaire +2 more sources
Elvitegravir for the treatment of HIV infection
Drugs of Today, 2014Advances in antiretroviral treatment have transformed HIV-1 infection from a deadly disease to a chronic one. Novel antiretroviral drugs have been approved for clinical use. In order to achieve long-term suppression of viremia, patients have to commit and take these drugs, or others approved in the future, for the rest of their lives.
openaire +2 more sources
Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and Maraviroc
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010The pharmacokinetic (PK) interaction between ritonavir-boosted elvitegravir (elvitegravir/r) and maraviroc was evaluated.Healthy subjects were randomized to receive elvitegravir/r (150/100 mg once daily) before or after elvitegravir/r plus maraviroc (150 mg twice daily) (group 1; n = 20) or receive maraviroc before or after maraviroc plus elvitegravir ...
Srinivasan, Ramanathan +5 more
openaire +2 more sources